Table 1 Overall study vaccine-related adverse events up to 50 days after the first vaccination.
From: Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
Adverse event, N (%) | ChulaCov19, (N = 120) up to 50 days | Placebo, (N = 30) up to 29 days | Comirnaty (post-Placebo), (N = 30) up to 50 days |
|---|---|---|---|
Overall adverse events | 119 (99.2%) | 26 (86.7%) | 30 (100%) |
Grade 3 | 16 (13.3%) | 1 (3.3%) | 0 (0.0) |
Grade 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Solicited adverse events | |||
All | 118 (98.3%) | 18 (60.0%) | 30 (100%) |
Grade 3 | 14 (11.7%) | 1 (3.3%) | 0 (0.0) |
Grade 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unsolicited adverse events | |||
All | 55 (45.8%) | 11 (36.7%) | 1 (3.3%) |
Grade 3 | 2 (1.7%) | 0 (0.0) | 0 (0.0) |
Grade 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Serious adverse event | 0 (0.0) | 0 (0.0) | 0 (0.0) |
